Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

159.29USD
1:57pm EDT
Change (% chg)

$1.87 (+1.19%)
Prev Close
$157.42
Open
$158.91
Day's High
$159.91
Day's Low
$158.36
Volume
160,655
Avg. Vol
310,014
52-wk High
$159.91
52-wk Low
$95.14

Latest Key Developments (Source: Significant Developments)

Abiomed's Impella CP receives expanded FDA approval for high-risk PCI procedures
Wednesday, 7 Dec 2016 07:00am EST 

Abiomed Inc :Abiomed Impella CP receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures.  Full Article

Abiomed Impella CP receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures
Wednesday, 7 Dec 2016 07:00am EST 

Abiomed Inc : Has expanded FDA pre-market approval for impella heart pump use in PCI to include impella cp heart pump .Abiomed impella cp receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures.  Full Article

Abiomed reports Q2 FY 2017 gaap earnings per share $0.20
Thursday, 27 Oct 2016 07:00am EDT 

Abiomed Inc : Announces Q2 FY 2017 revenue of $103 million, up 35% over prior year . Q2 gaap earnings per share $0.20 . Q2 revenue $103 million versus I/B/E/S view $103.2 million . Sees FY 2017 revenue $435 million to $445 million . Q2 earnings per share view $0.24 -- Thomson Reuters I/B/E/S . Says maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% .FY 2017 revenue view $446.3 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed receives FDA IDE approval for initiation of DTU prospective feasibility study
Thursday, 27 Oct 2016 07:00am EDT 

Abiomed Inc : Receives FDA IDE approval for initiation of door to unloading (DTU) prospective feasibility study . Says gets U.S. FDA approval of prospective feasibility study to evaluate use of Impella CP heart pump for unloading of left ventricle prior to primary percutaneous coronary intervention . Says trial will focus on feasibility and safety, and lay groundwork for a future trial .Says up to 50 patients at 10 sites will be included in study, which is expected to initiate in first half of calendar 2017.  Full Article

Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare
Tuesday, 27 Sep 2016 07:53am EDT 

Abiomed Inc : Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare . Co planning future discussions with PMDA relating to potential regulatory reviews of Impella CP and Impella RP later this fiscal year . Plans to start supporting patients in Japan during Q4 of FY '17 . Company will conduct a post-market surveillance on Impella usage .Says does not expect material revenue until FY'18.  Full Article

Abiomed reports Q1 gaap earnings per share of $0.29
Thursday, 28 Jul 2016 07:00am EDT 

Abiomed Inc : Is maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% . Fy2017 revenue view $439.5 million -- Thomson Reuters I/B/E/S . Abiomed announces q1 fy 2017 revenue of $103.0 million, up 40% over prior year . Q1 gaap earnings per share $0.29 . Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S . Q1 revenue $103 million versus i/b/e/s view $97.2 million .Is increasing lower end of its fiscal year 2017 revenue guidance with new range of $435 million to $445 million.  Full Article

Abiomed reports Q1 GAAP earnings per share of $0.29
Thursday, 28 Jul 2016 07:00am EDT 

Abiomed Inc : Abiomed announces q1 fy 2017 revenue of $103.0 million, up 40% over prior year . Q1 gaap earnings per share $0.29 . Q1 revenue $103 million versus i/b/e/s view $97.2 million . Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S . Abiomed inc says increasing lower end of its fiscal year 2017 revenue guidance with new range of $435 million to $445 million . Abiomed inc says maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% .Fy2017 revenue view $439.5 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed Inc gives FY 2017 revenue guidance
Tuesday, 3 May 2016 07:00am EDT 

Abiomed Inc:Gives FY 2017 guidance for total revenues to be in the range of $430 million to $445 million.  Full Article

Abiomed Inc gives Q3 2016 revenue guidance
Monday, 11 Jan 2016 04:00pm EST 

Abiomed Inc:Says reported preliminary unaudited Q3 2016 revenue of approximately $85.8 million.  Full Article

BRIEF-Abiomed receives FDA PMA approval for Impella RP for right heart failure

* Abiomed receives FDA PMA approval for Impella RP for right heart failure Source text for Eikon: Further company coverage: